XML 37 R27.htm IDEA: XBRL DOCUMENT
v3.22.1

Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables) | 9 Months Ended
--- | ---
Mar. 31, 2022
Notes Tables |
Schedule of Stockholders Equity [Table Text Block] | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Bio-Techne Shareholders |  | ​ | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Retained | ​ | Comprehensive | ​ | Noncontrolling | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Income(Loss) | ​ | Interest | ​ | Total
Balances at June 30, 2021 |  | 38,955 | ​ | $ | 390 | ​ | $ | 534,411 | ​ | $ | 1,085,461 | ​ | $ | (57,291) | ​ | $ | 8,263 | ​ | $ | 1,571,234
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | 69,615 | ​ |  | ​ | ​ |  | (634) | ​ |  | 68,981
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  |  | ​ |  | (6,925) | ​ |  | (39) | ​ |  | (6,964)
Share repurchases |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | ​
Common stock issued for exercise of options |  | 295 | ​ |  | 3 | ​ |  | 36,345 | ​ |  | (13,481) | ​ |  |  | ​ |  |  | ​ |  | 22,867
Common stock issued for restricted stock awards |  | 20 | ​ |  | 0 | ​ |  | 0 | ​ |  | (9,765) | ​ |  |  | ​ |  |  | ​ |  | (9,765)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | (12,493) | ​ |  | ​ | ​ |  |  | ​ |  | (12,493)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ |  | 11,396 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 11,396
Common stock issued to employee stock purchase plan |  | 3 | ​ |  | 0 | ​ |  | 1,358 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 1,358
Employee stock purchase plan expense |  | ​ | ​ | ​ | ​ | ​ |  | 341 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 341
Balances at September 30, 2021 |  | 39,273 | ​ | $ | 393 | ​ | $ | 583,851 | ​ | $ | 1,119,337 | ​ | $ | (64,216) | ​ | $ | 7,590 | ​ | $ | 1,646,955
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | 80,173 | ​ |  | ​ | ​ |  | (8,114) | ​ |  | 72,059
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  |  | ​ |  | 4,742 | ​ |  | 66 | ​ |  | 4,808
Share repurchases |  | (89) | ​ |  | (1) | ​ |  | ​ | ​ |  | (41,293) | ​ |  |  | ​ |  |  | ​ |  | (41,294)
Common stock issued for exercise of options |  | 134 | ​ |  | 1 | ​ |  | 18,604 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 18,605
Common stock issued for restricted stock awards |  | 1 | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | —
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | (12,576) | ​ |  | ​ | ​ |  |  | ​ |  | (12,576)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ |  | 13,701 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 13,701
Common stock issued to employee stock purchase plan |  | ​ | ​ |  | ​ | ​ |  | 6 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 6
Employee stock purchase plan expense |  | ​ | ​ | ​ | ​ | ​ |  | 267 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 267
Balances at December 31, 2021 |  | 39,319 | ​ | $ | 393 | ​ | $ | 616,429 | ​ | $ | 1,145,641 | ​ | $ | (59,474) | ​ | $ | (458) | ​ | $ | 1,702,531
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | 60,739 | ​ |  | ​ | ​ |  | (595) | ​ |  | 60,144
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  |  | ​ |  | 4,329 | ​ |  | (1) | ​ |  | 4,328
Share repurchases |  | (145) | ​ |  | (1) | ​ |  | ​ | ​ |  | (60,837) | ​ |  |  | ​ |  |  | ​ |  | (60,838)
Common stock issued for exercise of options |  | 84 | ​ |  | 1 | ​ |  | 10,494 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 10,495
Common stock issued for restricted stock awards |  | 1 | ​ |  | ​ | ​ |  | ​ | ​ |  | (159) | ​ |  |  | ​ |  |  | ​ |  | (159)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | (12,577) | ​ |  | ​ | ​ |  |  | ​ |  | (12,577)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ |  | 8,043 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 8,043
Common stock issued to employee stock purchase plan |  | 4 | ​ |  | ​ | ​ |  | 1,330 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 1,330
Employee stock purchase plan expense |  | ​ | ​ | ​ | ​ | ​ |  | 25 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 25
Balances at March 31, 2022 |  | 39,263 | ​ | ​ | 393 | ​ | ​ | 636,321 | ​ | ​ | 1,132,807 | ​ | ​ | (55,145) | ​ | ​ | (1,054) | ​ | ​ | 1,713,322
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Bio-Techne Shareholders |  | ​ | ​ |  |  | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-in | ​ | Retained | ​ | Comprehensive | ​ | Noncontrolling | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Income(Loss) | ​ | Interest | ​ | Total
Balances at June 30, 2020 |  | 38,453 | ​ | $ | 385 | ​ | $ | 420,536 | ​ | $ | 1,057,470 | ​ | $ | (97,199) | ​ | $ | — | ​ | $ | 1,381,192
Cumulative effect adjustments due to adoption of new accounting standards |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | (276) | ​ |  | ​ | ​ |  |  | ​ |  | (276)
Net earnings | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 33,395 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 33,395
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  |  | ​ |  | 14,057 | ​ |  | ​ | ​ |  | 14,057
Common stock issued for exercise of options |  | 117 | ​ |  | 1 | ​ |  | 13,727 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 13,728
Common stock issued for restricted stock awards |  | 25 | ​ |  | 0 | ​ |  | (0) | ​ |  | (4,890) | ​ |  |  | ​ |  |  | ​ |  | (4,890)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | (12,336) | ​ |  | ​ | ​ |  |  | ​ |  | (12,336)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ |  | 12,667 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 12,667
Common stock issued to employee stock purchase plan |  | 6 | ​ |  | 0 | ​ |  | 1,463 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 1,463
Employee stock purchase plan expense |  | ​ | ​ | ​ | ​ | ​ |  | 286 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 286
Balances at September 30, 2020 |  | 38,601 | ​ | $ | 386 | ​ | $ | 448,679 | ​ | $ | 1,073,362 | ​ | $ | (83,142) | ​ | $ | — | ​ | $ | 1,439,285
Non-controlling interest in Eminence | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 8,985 | ​ |  | 8,985
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | 46,274 | ​ |  | ​ | ​ |  | (130) | ​ |  | 46,144
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  |  | ​ |  | 18,904 | ​ |  | 83 | ​ |  | 18,987
Common stock issued for exercise of options |  | 161 | ​ |  | 2 | ​ |  | 16,748 | ​ |  | (2,482) | ​ |  |  | ​ |  |  | ​ |  | 14,268
Common stock issued for restricted stock awards |  | 3 | ​ |  | 0 | ​ |  | (0) | ​ |  | 0 | ​ |  |  | ​ |  |  | ​ |  | —
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | (12,392) | ​ |  | ​ | ​ |  |  | ​ |  | (12,392)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ |  | 15,471 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 15,471
Employee stock purchase plan expense |  | ​ | ​ | ​ | ​ | ​ |  | 106 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 106
Balances at December 31, 2020 |  | 38,765 | ​ | $ | 388 | ​ | $ | 481,004 | ​ | $ | 1,104,762 | ​ | $ | (64,238) | ​ | $ | 8,938 | ​ | $ | 1,530,854
Net earnings |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | 45,782 | ​ |  | ​ | ​ |  | (380) | ​ |  | 45,402
Other comprehensive income (loss) |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  |  | ​ |  | 215 | ​ |  | (69) | ​ |  | 146
Share repurchases | ​ | (120) | ​ | ​ | (1) | ​ | ​ | ​ | ​ | ​ | (43,177) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (43,178)
Common stock issued for exercise of options |  | 195 | ​ |  | 2 | ​ |  | 21,324 | ​ |  | (4,332) | ​ |  |  | ​ |  |  | ​ |  | 16,994
Common stock issued for restricted stock awards |  | 10 | ​ |  | 0 | ​ |  | (0) | ​ |  | (1,801) | ​ |  |  | ​ |  |  | ​ |  | (1,801)
Cash dividends |  | ​ | ​ | ​ | ​ | ​ |  |  | ​ |  | (12,446) | ​ |  | ​ | ​ |  |  | ​ |  | (12,446)
Stock-based compensation expense |  | ​ | ​ | ​ | ​ | ​ |  | 10,232 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 10,232
Common stock issued to employee stock purchase plan | ​ | 4 | ​ | ​ | 0 | ​ | ​ | 1,328 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,328
Employee stock purchase plan expense |  | ​ | ​ | ​ | ​ | ​ |  | 411 | ​ |  | ​ | ​ |  |  | ​ |  |  | ​ |  | 411
Balances at March 31, 2021 |  | 38,854 | ​ | $ | 389 | ​ | $ | 514,299 | ​ | $ | 1,088,788 | ​ | $ | (64,023) | ​ | $ | 8,489 | ​ | $ | 1,547,942
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2021 | ​ | $ | (6,193) | ​ | $ | (51,098) | ​ | $ | (57,291)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne | ​ |  | 7,757 | ​ |  | (9,599) | ​ |  | (1,842)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1) | ​ |  | 3,988 | ​ | $ | — | ​ | $ | 3,988
Balance as of March 31, 2022 (2) | ​ | $ | 5,552 | ​ | ​ | (60,697) | ​ | ​ | (55,145)
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Unrealized | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Gains | ​ | Foreign | ​ | ​ | ​
​ | ​ | (Losses) on | ​ | Currency | ​ | ​ | ​
​ | ​ | Derivative | ​ | Translation | ​ | ​ | ​
​ |  | Instruments |  | Adjustments |  | Total
Balance as of June 30, 2020 attributable to Bio-Techne | ​ | $ | (13,253) | ​ | $ | (83,946) | ​ | $ | (97,199)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne | ​ |  | (13) | ​ |  | 27,686 | ​ |  | 27,673
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(3) | ​ |  | 5,503 | ​ |  | — | ​ |  | 5,503
Balance as of March 31, 2021 (2) | ​ | $ | (7,763) | ​ | $ | (56,260) | ​ | $ | (64,023)
​
| (1) | Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $5,214 to interest expense and recorded a related tax benefit of $1,226 during the nine months ended March 31, 2022.
| (2) | The Company had a net deferred tax liability of $1,706 and a net deferred tax benefit of $2,394 included in the accumulated other comprehensive income loss as of March 31, 2022 and 2021, respectively.
| (3) | Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $6,662 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur in the nine months ended March 31, 2021. The Company also recorded a related tax benefit of $1,670 during the nine months ended March 31, 2021.

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration